Clinical Trials for Skin Cancer

201804077

An open-label, non-randomized, multi-arm, phase II trial to evaluate the efficacy of pembrolizumab combined with cetuximab in patients with recurrent/ metastatic head and neck squamous cell carcinoma (HNSCC) Phase II Principal Investigator Adkins, Douglas Disease…

201807035

Phase II Single-Arm Multi-Center Study of Adjuvant Ipilimumab in Combination with Nivolumab in Subjects with High-Risk Ocular Melanoma Phase II Principal Investigator Ansstas, George Disease Site Eye and Orbit Learn more about this study at:…

201809022

A Phase 3, Randomized, Open-label Study of NKTR-214 Combined with Nivolumab Versus Nivolumab in Participants with Previously Untreated Unresectable or Metastatic Melanoma Phase III Principal Investigator Ansstas, George Disease Site Melanoma, Skin Learn more about…

201812031

STAMP: Surgically Treated Adjuvant Merkel cell carcinoma with Pembrolizumab, a Phase III Trial Phase III Principal Investigator Ansstas, George Disease Site Other Skin Learn more about this study at: clinicaltrials.gov

201902130

A PHASE II RANDOMIZED STUDY OF ADJUVANT VERSUS NEOADJUVANT MK-3475 (PEMBROLIZUMAB) FOR CLINICALLY DETECTABLE STAGE III-IV HIGH RISK MELANOMA Phase II Principal Investigator Ansstas, George Disease Site Melanoma, Skin Learn more about this study at:…

201903017

A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF RO7198457 IN COMBINATION WITH PEMBROLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED MELANOMA Phase II Principal Investigator Ansstas, George Disease Site…

201903162

Phase II Study of Optune Device – TT Fields plus Nivolumab and Ipilimumab for Melanoma with Brain Metastasis Phase II Principal Investigator Ansstas, George Disease Site Brain and Nervous System; Melanoma, Skin; Metastatic Disease Learn…

201904155

A phase 1b/2a, open label study to evaluate anti-tumor efficacy and safety of rhIL-7-hyFc (NT-I7) in combination with anti-PD-L1 (atezolizumab) in patients with anti-PD-1/PD-L1 naïve or relapsed/refractory high-risk skin cancers Phase I/II Principal Investigator Ansstas,…

201905153

A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma Phase II Principal Investigator Ansstas, George Disease Site Melanoma, Skin…

201905156

A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo after Surgery and Radiation Therapy in Patients with High Risk Cutaneous Squamous Cell Carcinoma Phase III Principal Investigator Ansstas, George Disease Site Other Skin Learn…

201907032

A phase 2 study of combination therapy with an IL-15 superagonist (N-803), off-the-shelf CD16-targeted natural killer cells (haNK), and avelumab without cytotoxic chemotherapy in subjects with Merkel cell carcinoma (MCC) that has progressed on or…

202003124

Adjuvant pembrolizumab and hypofractionated radiation therapy for the treatment of mucosal melanoma Phase I/II Principal Investigator Ansstas, George Disease Site Melanoma, Skin Learn more about this study at: clinicaltrials.gov

202004065

A Phase II Neoadjuvant Study of Encorafenib With Binimetinib in Patients With Resectable Locoregional Metastases From Cutaneous or Unknown Primary Melanoma (Stages III N1B/C/D) Phase II Principal Investigator Keller, Jesse Disease Site Melanoma, Skin; Metastatic…

202008099

A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined with Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12) Phase III (Cancer Control) Principal…

202010093

A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop) Phase II Principal Investigator Keller, Jesse Disease Site Melanoma, Skin Learn more about this study at: clinicaltrials.gov

202011137

A PHASE Ib, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF BELVARAFENIB AS A SINGLE AGENT AND IN COMBINATION WITH EITHER COBIMETINIB OR COBIMETINIB PLUS ATEZOLIZUMAB IN PATIENTS WITH NRAS-MUTANT ADVANCED MELANOMA…

202103077

Phase 1/2 Study of an EZH2 inhibitor (tazemetostat) in combination with dual BRAF/MEK inhibition in patients with BRAF-mutated metastatic melanoma who progressed on prior BRAF/MEK inhibitor therapy Phase I/II Principal Investigator Johanns, Tanner Disease Site…